RV-PA uncoupling is associated with increased mortality in transthyretin amyloid cardiomyopathy treated with tafamidis

被引:0
|
作者
Schwarting, Stephanie K. [1 ,2 ]
Poledniczek, Michael [2 ,3 ]
Metodiev, Yuliyan [1 ]
Stolz, Lukas [1 ]
Hofmann, Eva [2 ]
Hegenbart, Ute [4 ]
Schoenland, Stefan [4 ]
Kaeaeb, Stefan [1 ,5 ]
Massberg, Steffen [1 ]
Frey, Norbert [2 ]
Aus Dem Siepen, Fabian [2 ]
机构
[1] LMU Univ Hosp Munich, Dept Med 1, Marchionini str 15, D-81377 Munich, Germany
[2] Univ Hosp Heidelberg, Dept Cardiol Angiol & Resp Med, Neuenheimer Feld 410, Heidelberg, Germany
[3] Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Vienna, Austria
[4] Univ Hosp Heidelberg, Dept Internal Medicine5, Neuenheimer Feld 410, Heidelberg, Germany
[5] European Reference Network Rare Low Prevalence & C, Amsterdam, Netherlands
关键词
RV-PA coupling; Amyloidosis; Transthyretin; Echocardiography; TAPSE/PASP-ratio; HEART-FAILURE; CLINICAL-OUTCOMES; PROGNOSTIC VALUE; REPAIR; IMPACT;
D O I
10.1007/s00392-024-02576-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The right ventricle to pulmonary artery coupling (RV-PAc) describes the right ventricle's ability to adjust to an increased afterload. In case of transthyretin amyloid cardiomyopathy (ATTR-CM), impaired RV-PAc can result from increased left ventricular diastolic stiffness due to fibril deposition. Objectives While RV-PAc is a validated prognostic parameter in pulmonary arterial hypertension (PAH), its prognostic relevance in ATTR-CM remains unknown. We sought to evaluate the prognostic implications of impaired RV-PAc on survival in ATTR-CM. Methods In this multicentre study, RV-PAc was investigated by the echocardiographic surrogate of ratio of tricuspid annular plane systolic excursion to estimated pulmonary arterial systolic pressure (TAPSE/PASP) in 418 ATTR-CM patients, all treated with a TTR stabilizer. The primary outcome was all-cause mortality. Results Within a median time of 1.52 [IQR 0.72-2.56] years after diagnosis, 49 (11.7%) patients died. In multivariate Cox regression analysis impaired RV-PAc was a strong independent predictor of mortality (Hazard Ratio (HR) 2.16, 95% Confidence Interval (CI) 1.14-4.07, p = 0.018). RV-PAc ratio at first presentation emerged as a robust marker for risk stratification with a determined optimal cut-off of 0.382 mm/mmHg (area under the curve (AUC) 0.73, 95% CI 0.65-0.81). Patients with RV-PAc ratio <= 0.382 mm/mmHg exhibited significantly lower survival (HR 4.17, 95% CI 2.21-7.87, p < 0.001) within 3 years of follow up than those with RV-PAc ratio above the cut-off (Graphical Abstract). Conclusion Impaired adaptation of the RV to increased afterload is associated with worse outcome in ATTR-CM patients. RV-PAc ratio can serve as an echocardiographic predictor for all-cause mortality. Therefore, the determination of RV-PAc could improve risk stratification for ATTR-CM patients.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis
    Bampatsias, Dimitrios
    Wardhere, Abdirahman
    Zeldin, Lawrence
    Mirabal-Santos, Alfonsina
    Weinsaft, Ariel Y.
    Levy, Juliana C.
    Smiley, Dia
    Teruya, Sergio L.
    Maurer, Mathew S.
    HEART, 2025,
  • [22] Prognostic factors associated with survival in patients with wild-type transthyretin amyloid cardiomyopathy, treated with tafamidis
    Zemljic, G.
    Frljak, S.
    Poglajen, G.
    Zorz, N.
    Cerar, A.
    Okrajsek, R.
    Bajec, T.
    Vrtovec, B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 162 - 162
  • [23] Right Ventricular Dysfunction in Group 3 PH: Male Gender is Associated With RV-PA Uncoupling
    Rose, L.
    Prins, K. W.
    Archer, S. L.
    Pritzker, M.
    Weir, E. K.
    Thenappan, T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S54 - S54
  • [24] Tafamidis and Incidence of Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy
    Girvin, Zachary P.
    Sweat, Austin O.
    Kochav, Stephanie M.
    Maurer, Mathew S.
    Dizon, Jose
    Wan, Elaine Y.
    Biviano, Angelo
    Garan, Hasan
    Yarmohammadi, Hirad
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2023, 9 (04) : 586 - 587
  • [25] Tafamidis in Transthyretin Amyloid Cardiomyopathy Effects on Transthyretin Stabilization and Clinical Outcomes
    Maurer, Mathew S.
    Grogan, Donna R.
    Judge, Daniel P.
    Mundayat, Rajiv
    Packman, Jeff
    Lombardo, Ilise
    Quyyumi, Arshed A.
    Aarts, Janske
    Falk, Rodney H.
    CIRCULATION-HEART FAILURE, 2015, 8 (03) : 519 - 526
  • [26] Tafamidis Stabilizes Transthyretin and Improves Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy
    Falk, Rodney
    Maurer, Matthew
    Fedson, Savitri
    Judge, Daniel
    Zeldenrust, Steven
    Quyyumi, Arshed
    Pano, Arian
    Packman, Jeff
    Grogan, Donna
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (08) : S56 - S56
  • [27] Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy
    Park, Jonathan
    Egolum, Ugochukwu
    Parker, Shanea
    Andrews, Ebony
    Ombengi, David
    Ling, Hua
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (05) : 470 - 477
  • [28] TREATING TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: A COMPARISON OF DIFLUNISAL AND TAFAMIDIS
    Gilad, Amir
    Joshi, Tracy
    Mendelson, Lisa
    Berk, John
    Sanchorawala, Vaishali
    Ruberg, Frederick
    Siddiqi, Omar
    Gopal, Deepa
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3296 - 3296
  • [29] Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy
    Rapezzi, C.
    Kristen, A., V
    Gundapaneni, B.
    Sultan, M. B.
    Hanna, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2115 - 2115
  • [30] A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
    Singh, Bishnu Mohan
    Bohara, Narayan
    Gautam, Kamal
    Basnet, Madan
    Sistu, K. C.
    Binod, K. C.
    Raut, Anuradha
    Phudong, Abisha
    Gautam, Jeevan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)